Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

This study has been completed.
Sponsor:
Information provided by:
Baskent University
ClinicalTrials.gov Identifier:
NCT00290394
First received: February 9, 2006
Last updated: NA
Last verified: March 2004
History: No changes posted

February 9, 2006
February 9, 2006
March 2004
Not Provided
Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure–reducing effects.

The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks’ treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
Drug: rosiglitazone(drug), blood pressure lowering effect
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
August 2004
Not Provided

Inclusion Criteria:

  • Blood pressure of patients were in normotensive limits according to the JNC VII
  • Diabetes mellitus treated with oral antidiabetics or diet

Exclusion Criteria:

  • Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
  • Anti-hypertensive treatment
Both
49 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT00290394
KA03/181
Not Provided
Not Provided
Baskent University
Not Provided
Study Director: Neslihan B Tutuncu, MD Medical Doctor, Endocrynology
Baskent University
March 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP